Tag: ESC 2022

TIME: The Treatment in Morning versus Evening Blood Pressure Study, in Brief

DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening

ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease

COVID-19 Vaccine Safe in Patients With Heart Failure

No Benefit of Routine Stress Test POST-PCI in High-Risk Patients

TIME: CV Events Similar With Evening or Morning Dose of BP Meds

Barcelona Beckons for First Hybrid ESC Congress

Early Signal of Benefit for Empagliflozin in Acute MI: EMMY

No Invasive Strategy Benefit at 5 Years in ISCHEMIA-CKD Extension Study

PANTHER: Should Clopidogrel Become the ‘New Aspirin’ in CAD?